GlassScriptPhysician profile
Shaukat Matin
NPI 1295792943
$2,242.14
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $142 · 2021: $181 · 2022: $413 · 2023: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $281.02 | 2019-2023 | |
| Novo Nordisk INC | $264.32 | 2019-2023 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $174.58 | 2022-2023 | Livalo, Seglentis |
| Abbvie INC. | $153.50 | 2022-2023 | |
| Genzyme Corporation | $127.33 | 2023 | |
| Lilly USA, LLC | $125.24 | 2019-2023 | Mounjaro, Trulicity |
| Abbott Laboratories | $113.07 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $104.22 | 2019-2023 | Otezla, Repatha |
| Dexcom, INC. | $103.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $99.15 | 2019-2022 | |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $97.17 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $90.49 | 2023 | Rexulti, Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $88.83 | 2019-2023 | Eliquis |
| Pfizer INC. | $75.94 | 2019-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.39 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.00 | 2019-2022 | |
| Allergan, INC. | $37.82 | 2019 | |
| Exact Sciences Corporation | $35.58 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.46 | 2019 | |
| Esperion Therapeutics, INC. | $12.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaukat Matin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.